Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis

ABSTRACT

Purpose: To compare the efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T) and dexamethasone 0.1%/tobramycin 0.3% (DM/T) ophthalmic suspensions in reducing select signs of blepharitis.

Methods: Data were pooled from two studies (one from the USA; one from China) of adults (n = 627) with blepharokeratoconjunctivitis treated with LE/T or DM/T four times daily for 2 weeks (safety population). Efficacy analyses included 495 eyes (247 LE/T, 248 DM/T) with any baseline sign of blepharitis.

Results: At Day 15, the least squares mean change from baseline in composite blepharitis severity was similar between LE/T (–2.86) and DM/T (–2.99) (90% CI for mean treatment difference: –0.35, 0.11). Intraocular pressure (IOP) increases ≥10 mmHg over baseline were reported for 1 US patient (DM/T group) and 19 Chinese patients (6 LE/T; 13 DM/T).

Conclusions: LE/T was similarly effective in reducing the signs of blepharitis compared with DM/T, but demonstrated a better safety profile with respect to changes in IOP.

Keywords:

• Blepharitis
• dexamethasone
• loteprednol etabonate
• tobramycin

FUNDING

Statistical analyses were performed by Thomas Sexton, PhD, of Stony Brook University (Stony Brook, NY) and funded by Bausch & Lomb. Editorial and writing assistance was provided by Churchill Communications (Maplewood, NJ), funded by Bausch & Lomb. The authors were active participants in manuscript development and retain full responsibility for the content.

Additional information

Funding

Statistical analyses were performed by Thomas Sexton, PhD, of Stony Brook University (Stony Brook, NY) and funded by Bausch & Lomb. Editorial and writing assistance was provided by Churchill Communications (Maplewood, NJ), funded by Bausch & Lomb. The authors were active participants in manuscript development and retain full responsibility for the content.